euro-pathology-hematologic-oncology-2018-posters

3 / 6

Page 57
Notes:
conferenceseries.com
Euro Pathology 2018 | Hematologic Oncology 2018
June 20-21, 2018
Volume 8 Journal of Clinical & Experimental Pathology
ISSN : 2161-0681
15 th EUROPEAN PATHOLOGY CONGRESS
&
LEUKEMIA AND HEMATOLOGIC ONCOLOGY
June 20-21, 2018 | Paris, France
14th International Conference on
JOINT EVENT
Characterization of pre-clinical models of luminal B breast cancer in orthotopic and bone metastasis settings
Anniina Luostarinen1, Tiina E Kähkönen1, Mari I Suominen1, Jussi M Halleen1, Jenni H E Mäki-Jouppila1, Teppo Haapaniemi2 and Jenni Bernoulli1
1Pharmatest Services, Finland
2BioSiteHisto, Finland
Luminal B breast cancer is a hormone receptor (ER and/or PR) positive and HER2 positive or negative carcinoma with high
proliferation rate and poor prognosis. Luminal B breast cancer has increased risk to relapse in incurable bone metastasis. Scarce
availability of pre-clinical luminal B type of breast cancer bone metastasis models sets a challenge for development of more efficient
treatments for luminal B breast cancer where therapeutic resistance is common. Aim of this study was to verify and compare the
ER, PR and HER2 status in luminal B type orthotopic and bone metastasis xenograft models. BT-474 (ER+, PR+, HER2+) human
breast ductal carcinoma cells were inoculated into the mammary fat pad or tibia bone marrow of female immunodeficient CIEA
NOG mice, presenting orthotopic and bone metastasis models, respectively. The orthotopic study was performed with and without
estradiol (E2) supplement and the bone metastasis study without E2 supplement. Tumor growth was followed for eight weeks and
histopathological evaluation and ER, PR and HER2 immunoperoxidase stainings were performed at endpoint. The orthotopic tumors
with E2 supplement expressed ER, PR and HER2. Without E2 supplement the tumors in the orthotopic and bone metastasis studies
were ER and HER2 positive but PR negative. Orthotopic tumors without E2 grew only to 38% of the animals, whereas 100% take rate
was observed with E2 supplement and in the bone metastasis study. This study highlights the importance of careful characterization
of pre-clinical models when developing new cancer therapies. Focus should be addressed not only to primary tumors but also to
bone metastases. The characterized orthotopic and bone metastasis models can be used to study new treatments for luminal B breast
cancer, e.g. targeting the IGF-1 or FGF signaling pathways that are known to affect treatment resistance and cell proliferation.
Biography
Anniina Luostarinen has graduated in Biomedical Sciences major from University of Turku in 2016. After upgrading her education from a Biomedical Laboratory
Scientist who graduated in 2006, she has worked in Pharmatest Services, a preclinical contract research organization, concentrating in development of cancer and
skeletal disease treatments. Her whole career has focused on the physiology of bone and the interaction of bone microenvironment and cancer. Particularly the
bone histology as well as radiology is in her interest.
Anniina Luostarinen et al., J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C1-046